[O24] DIFFERENCES IN POSTPRANDIAL LIPID METABOLISM IN PATIENTS WITH PROTEASE INHIBITOR (PI)-ASSOCIATED AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)-ASSOCIATED LIPODYSTROPHY

7th Annual Conference Of The British HIV Association [BHIVA]

27 – 29 April 2001, The Hove Centre, Brighton

[TITLE:] DIFFERENCES IN POSTPRANDIAL LIPID METABOLISM IN PATIENTS WITH PROTEASE INHIBITOR (PI)-ASSOCIATED AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)-ASSOCIATED LIPODYSTROPHY

[AUTHOR(S):] L Ware¹, JM Morlese², G Burdge¹, A Jackson¹, BG Gazzard², S Wootton¹
¹ Institute of Human Nutrition, University of Southampton, ² Chelsea and Westminster Hospital, London, UK

BHIVA Conf 2001 Apr 27-29;7:O24

OBJECTIVE: To use labelled fatty acids to describe the postprandial metabolism of dietary lipid in HIV-positive men on dual NRTI therapy with self-reported lipodsytrophy who had never received a PI (NRTI-L: n=7).

METHODS: [1-¹³C]Palmitic acid was given as part of a test meal following an overnight fast. Total plasma triacylglycerol (TAG), non-esterified fatty acid (NEFA), ¹³C-TAG and ¹³C-NEFA were measured before and for 7 hours after the meal by GC-C-IRMS. The results were then compared with those in a PI-associated lipodystrophy group of HIV-positive men (PI-L: n=6) using the same study design.

RESULTS: NRTI-L patients had lower plasma TAG and NEFA concentrations at baseline with smaller changes in TAG and NEFA throughout the postprandial period than PI-L patients (all P<0.05). NRTI-L patients had lower and less prolonged increases in ¹³C-TAG than those in PI-L patients [threefold smaller area under the curve (AUC); P<0.05] but greater and more prolonged increases in ¹³C-NEFA concentrations (1.5-fold greater AUC; P<0.05).

CONCLUSIONS: While the PI-treated lipodystrophy group showed an increased retention time of dietary lipid within the circulation as lipoprotein TAG, the NRTI-treated lipodystrophy group showed an increased retention time of dietary lipid within the circulation as NEFA. These results suggest that there may be different effects of these two drug classes on lipid metabolism in vivo which may influence the development of the changes in body composition.

PRESENTING AUTHOR: JM Morlese

Download Presentation

010427
O24

Copyright © 2001, 2011 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD